CAROLINE GLICK: Open Payments
NPI 1386070118 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,634 in 55 payments from 23 companies in 2025. Trend: 2023 $1,099 · 2024 $1,075 · 2025 $1,634
Food & beverage: $1,634
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 8 | $297 |
| Arcutis Biotherapeutics, Inc. | 3 | $284 |
| Janssen Biotech, Inc. | 5 | $184 |
| GENZYME CORPORATION | 4 | $140 |
| Amgen Inc. | 4 | $107 |
| Novartis Pharmaceuticals Corporation | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| PFIZER INC. | 3 | $56 |
| ABBVIE INC. | 3 | $51 |
| Biofrontera Inc. | 2 | $47 |
Products named: Zoryve, NEMLUVIO, TREMFYA, DUPIXENT, OTEZLA, COSENTYX, AKLIEF, CIBINQO.
Industry payments across MD — which companies pay providers there.
